Floatz logo

83 assets in Biliary Tract Cancer

Therapeutic assets addressing Biliary Tract Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Cis-Diamminedichloroplatinum Ii
Biliary Tract Cancer
Merck Sharp & Dohme LLCP3BB (67)
Epirubicin
Biliary Tract Cancer
Merck Sharp & Dohme LLCP3BB (66)
Pembrolizumab
Biliary Tract Cancer
Merck Sharp & Dohme LLCP3BB (66)
Fluorouracilum
Biliary Tract Cancer
Shenzhen Xinhe BiomedicalP2B (62)
Capecitabine
Biliary Tract Cancer
Zhejiang Cancer HospitalP2B (61)
Datopotamab Deruxtecan
Biliary Tract Cancer
AstraZenecaP2B (60)
Durvalumab
Biliary Tract Cancer
Replimune, Inc.P2B (60)
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer
Biliary Tract Cancer
AHS Cancer Control AlbertaP2B (60)
Oxaliplatin
Biliary Tract Cancer
Zhejiang Cancer HospitalP1/2B (60)
Atezolizumab
Biliary Tract Cancer
Replimune, Inc.P2B (59)
Carboplatin
Biliary Tract Cancer
University of Texas Southwestern Medical CenterP2B (59)
Levofolinic Acid
Biliary Tract Cancer
Shenzhen Xinhe BiomedicalP2B (59)
Lenvatinib
Biliary Tract Cancer
AstraZenecaP2B (58)
Ipilimumab
Biliary Tract Cancer
Olivia Newton-John Cancer Research InstituteP2B (57)
Irinotecan
Biliary Tract Cancer
Shenzhen Xinhe BiomedicalP2B (57)
Nivolumab
Biliary Tract Cancer
Olivia Newton-John Cancer Research InstituteP2B (57)
Rilvegostomig
Biliary Tract Cancer
AstraZenecaP2CCC (55)
Anbenitamab
Biliary Tract Cancer
Peking University Cancer Hospital & InstituteP2CCC (53)
Erfonrilimab
Biliary Tract Cancer
Peking University Cancer Hospital & InstituteP2CCC (53)
Hydroxychloroquine
Biliary Tract Cancer
Northwestern UniversityP2CCC (53)
Olanzapine
Biliary Tract Cancer
OHSU Knight Cancer InstituteP2CCC (53)
Ibentatug
Biliary Tract Cancer
ZielBio, Inc.P1/2CCC (52)
Apsolol
Biliary Tract Cancer
AHS Cancer Control AlbertaP2CCC (51)
azd0901
Biliary Tract Cancer
AstraZenecaP2CCC (51)
bi 907828
Biliary Tract Cancer
Institut BergoniéP2CCC (51)
Brigimadlin
Biliary Tract Cancer
Boehringer IngelheimP2CCC (51)
Ezabenlimab
Biliary Tract Cancer
Institut BergoniéP2CCC (51)
Ligufalimab
Biliary Tract Cancer
University of Texas Southwestern Medical CenterP2CCC (51)
Prednisolone
Biliary Tract Cancer
AstraZenecaP2CCC (51)
Prednisone
Biliary Tract Cancer
AstraZenecaP2CCC (51)
Rain-32
Biliary Tract Cancer
Rain Oncology IncP2CCC (51)
rp2
Biliary Tract Cancer
Replimune, Inc.P2CCC (51)
Serplulimab
Biliary Tract Cancer
RenJi HospitalP2CCC (51)
Surufatinib
Biliary Tract Cancer
RenJi HospitalP2CCC (51)
Volrustomig
Biliary Tract Cancer
AstraZenecaP2CCC (51)
Avzo-1418
Biliary Tract Cancer
Avenzo Therapeutics, Inc.P1/2CCC (48)
Bms-986504
Biliary Tract Cancer
Northwestern UniversityP1/2CCC (48)
Camizestrant
Biliary Tract Cancer
AstraZenecaP1/2CCC (48)
Inv-8989
Biliary Tract Cancer
Shenzhen Ionova Life Sciences Co., Ltd.P1/2CCC (48)
Palacaparib
Biliary Tract Cancer
AstraZenecaP1/2CCC (48)
Puxitatug Samrotecan
Biliary Tract Cancer
AstraZenecaP1/2CCC (48)
Saruparib
Biliary Tract Cancer
AstraZenecaP1/2CCC (48)
T-Dxd
Biliary Tract Cancer
AstraZenecaP1/2CCC (48)
vb15010
Biliary Tract Cancer
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.P1/2CCC (48)
Devimistat
Biliary Tract Cancer
Northwestern UniversityP2CC (47)
H-Gamma1 Heavy Chain Anti-Cd47 (1-444), G1V92-1 Vh E44, Ch1 E77 [Vh E44 (Homo Sapiens Ighv1-46*01 (87.6%) Q44>E (39') -(Ighd) -Ighj4*01 (100%), Cdr-Imgt [8.8.7] (26-33.51-58.97-103)) (1-114) -Homo Sapiens Ighg1*01, G1M17,1 Ch1 K120, Ch3 D12, L14, Ch1 E77, G1V93 Ch1 C12, G1V37 H S5, G1V74 Ch3 C10, G1V32 Ch3 W22 (Knob) (Ch1 K12>C (130), G77>E (163), K120 (211) (115-212), Hinge 1-15 C5>S (217) (213-227), Ch2 (228-337), Ch3 S10>C (351), D12 (353), L14 (355), T22>W (363) (338-442), Chs (443-444)) (115-444)], (130-209')- Disulfide With L-Kappa Light Chain Anti-Cd47 (1'-214') Kv92-1 V-Kappa K44, C-Kappa K3 [V-Kappa K44 (Homo Sapiens Igkv3-20*01 (83.3%) Q44>K (38') -Igkj1*01 (91.7%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc*01 (98.1%) Km3 A45.1, V101, K3, Kcv37 C121, S126 (C-Kappa S3>K (114'), A45.1 (153'), V101 (191'), F121>C (209'), C126>S (214')) (108'-214')]; H-Gamma1 Heavy Chain Anti-Cldn18 (1-449), G1V92-2 Vh K44, Ch1 K77 [Vh K44 (Homo Sapiens Ighv3-48*01 (87.8%) Q44>K (39'') -(Ighd) -Ighj4*01 (92.9%), Cdr-Imgt [8.8.12] (26''-33''.51''-58''.97''-108'')) (1''-119'') -Homo Sapiens Ighg1*01, G1M17,1 Ch1 K120, Ch3 D12, L14, Ch1 K77, G1V75 Ch3 C5, G1V33 Ch3 S22, A24, V86 (Hole) (Ch1 G77>K (168''), K120 (216'') (120''-217''), Hinge 1-15 (218''-232''), Ch2 (233''-342''), Ch3 Y5>C (351''), D12 (358''), L14 (360''), T22>S (368''), L24>A (370''), Y86>V (409'') (343''-447''), Chs (448''-449'')) (120''-449'')], (222''-220''')-Disulfide With L-Kappa Light Chain Anti-Cldn18 (1'''-220''') Kv92-2 V-Kappa E44, C-Kappa E3 [V-Kappa E44 (Musmus/Homsap (Mus Musculus Igkv8-19*01 (79.2%) Q44>E (44''') -Igkj2*03 (81.8%) S120>Q (106'''), L124>V (110''')/Homo Sapiens Igkv1-39*01 (78.2%) Q44>E (44''') -Igkj1*01 (100%), Cdr -Imgt [12.3.9] (27'''-38'''.56'''-58'''.95'''-103''')) (1'''-113''') -Homo Sapiens Igkc*01 (99.1%) Km3 A45.1, V101, E3 (C-Kappa S3>E (120'''), A45.1 (159'''), V101 (197''')) (114'''-220''')]; Dimer (223-228'':226-231'':351-351'')-Trisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa
Biliary Tract Cancer
Phanes TherapeuticsP1/2CC (47)
Immunoglobulin G1, Anti-(Human Programmed Death-Ligand 1) (Human Monoclonal Sti-3031 .Gamma.1-Chain), Disulfide With Human Monoclonal Sti-3031 .Lambda.-Chain, Dimer
Biliary Tract Cancer
Sorrento Therapeutics, Inc.P2CC (47)
Docetaxel
Biliary Tract Cancer
Cantargia ABP1/2CC (46)
Immunoglobulin G1, Anti-(Human Interleukin-1 Receptor Accessory Protein) (Human-Mus Musculus Monoclonal Can04 .Gamma.1-Chain), Disulfide With Human-Mus Musculus Monoclonal Can04 .Kappa.-Chain, Dimer
Biliary Tract Cancer
Cantargia ABP1/2CC (46)
Tinengotinib
Biliary Tract Cancer
TransThera Sciences (Nanjing), Inc.P1/2CC (46)
Showing 1 to 50 of 83 assets
PreviousPage 1 of 2Next